Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 5/20 | 0.38 |
| ▸ | CTSK | P43235 | 5/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.37 |
| ▸ | FABP7 | O15540 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 3/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2529726 | 1.00 | KMT2A (0.40) | KMT2AGBA1CTSSCTSKFABP5 | |
| SCHEMBL940142 | 1.00 | KMT2A (0.40) | KMT2AGBA1CTSSCTSKFABP5 | |
| SCHEMBL2531446 | 0.87 | KMT2A (0.40) | KMT2AGBA1FABP5FABP7EPHX2 | |
| SCHEMBL1480822 | 0.87 | KMT2A (0.40) | KMT2AGBA1FABP5FABP7EPHX2 | |
| SCHEMBL8214544 | 0.87 | KMT2A (0.42) | KMT2AGBA1FABP5FABP7EPHX2 | |
| SCHEMBL1480821 | 0.87 | KMT2A (0.40) | KMT2AGBA1FABP5FABP7EPHX2 | |
| SCHEMBL1481301 | 0.87 | KMT2A (0.40) | KMT2AGBA1FABP5FABP7EPHX2 | |
| SCHEMBL2531445 | 0.87 | KMT2A (0.40) | KMT2AGBA1FABP5FABP7EPHX2 | |
| SCHEMBL2535254 | 0.85 | KMT2A (0.38) | KMT2AGBA1FABP5FABP7EPHX2 | |
| SCHEMBL2533038 | 0.85 | KMT2A (0.38) | KMT2AGBA1FABP5FABP7EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150164912-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2015-06-18 | — | — | US | disclosed |
| US-8933109-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA LIMITED (GB) | 2015-01-13 | — | — | US | disclosed |
| US-20140038944-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2014-02-06 | — | — | US | disclosed |
| US-8552202-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2013-10-08 | — | — | US | disclosed |
| US-20130150345-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
| US-8389737-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-8039641-B2 | Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates | AMURA THERAPEUTICS LIMITED (GB) | 2011-10-18 | — | — | US | disclosed |
| US-8008290-B2 | Compounds | AMURA THERAPEUTICS LIMITED (GB) | 2011-08-30 | — | — | US | disclosed |
| US-20110009385-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| US-20110009386-A1 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| US-20090192322-A1 | Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150345-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KMT2A 4741/4885GBA1 484/4885CTSS 1/4885 |
| US-20110009385-A1 | COMPOUNDS | CTSK, CTSS, MMP9 | KMT2A 4690/4885GBA1 482/4885CTSS 2/4885 |
| US-20150164912-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KMT2A 4741/4885GBA1 484/4885CTSS 1/4885 |
| US-20140038944-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KMT2A 4741/4885GBA1 484/4885CTSS 1/4885 |
| US-20110009386-A1 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KMT2A 4719/4885GBA1 319/4885CTSS 1/4885 |
| US-20090192322-A1 | Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates | CYP4F8, CYP2C8, AVPR1B | KMT2A 3122/4885GBA1 647/4885CTSS 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.